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A recent increase in the literature regarding the evidence base for clozapine has made it increasingly difficult for clinicians to judge
“best evidence” for clozapine use. As such, we aimed at elucidating the state-of-the-art for clozapine with regard to efficacy,
effectiveness, tolerability, and management of clozapine and clozapine-related adverse events in neuropsychiatric disorders. We
conducted a systematic PRISMA-conforming quantitative meta-review of available meta-analytic evidence regarding clozapine use.
Primary outcome effect sizes were extracted and transformed into relative risk ratios (RR) and standardized mean differences (SMD).
The methodological quality of meta-analyses was assessed using the AMSTAR-2 checklist. Of the 112 meta-analyses included in our
review, 61 (54.5%) had an overall high methodological quality according to AMSTAR-2. Clozapine appears to have superior effects
on positive, negative, and overall symptoms and relapse rates in schizophrenia (treatment-resistant and non-treatment-resistant
subpopulations) compared to first-generation antipsychotics (FGAs) and to pooled FGAs/second-generation antipsychotics (SGAs)
in treatment-resistant schizophrenia (TRS). Despite an unfavorable metabolic and hematological adverse-event profile compared to
other antipsychotics, hospitalization, mortality and all-cause discontinuation (ACD) rates of clozapine surprisingly show a pattern of
superiority. Our meta-review outlines the superior overall efficacy of clozapine compared to FGAs and most other SGAs in
schizophrenia and suggests beneficial efficacy outcomes in bipolar disorder and Parkinson’s disease psychosis (PDP). More clinical
studies and subsequent meta-analyses are needed beyond the application of clozapine in schizophrenia-spectrum disorders and
future studies should be directed into multidimensional clozapine side-effect management to foster evidence and to inform future
guidelines.
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INTRODUCTION
Clozapine—considered the most effective antipsychotic—was
introduced in the early 1970s for the treatment of schizophrenia.
First, clozapine was believed to have not only superior efficacy but
also to have overall better tolerability compared to first-generation
antipsychotics (FGA) due to a low risk for extrapyramidal
symptoms (EPS). However, in 1975, clozapine was voluntarily
withdrawn since 17 out of 2660 (0.7%) patients treated with
clozapine in Finland developed agranulocytosis and eight patients
subsequently died [1]. In 1988, Kane et al. confirmed clozapine’s
safety and superiority vs. chlorpromazine in treatment-resistant
schizophrenia (TRS) [2], and subsequently, the Federal Drug
Agency (FDA) and other health authorities approved its re-
introduction for the indication of TRS with regular hematological
monitoring.
Evidence-based treatment guidelines for the management of
difficult-to-treat schizophrenia currently recommend clozapine
[3–5]. Nevertheless, definitions of TRS, typically involving two
failed trials of different non-clozapine antipsychotics, differ
significantly across guidelines [6] as do criteria for TRS in clinical
trials: if TRS is operationalized at all, it differs in up to 95% of trials
[7]. A lack of consensus is also represented in the extent and
frequency of mandatory safety monitoring procedures beyond
hematological monitoring during clozapine treatment according
to the respective national regulations [6]. Further indications or
recommendations, when clozapine can be applied in clinical
practice, are poorly harmonized: in certain European countries,
(e.g. Germany, the Netherlands) clozapine is indicated for the
treatment of Parkinson’s disease psychosis (PDP), whereas in the
US it was given a Level B recommendation by the American
Academy of Neurology (AAN) for this indication. Furthermore, the
FDA approved clozapine as the first agent indicated for suicidality
in people with schizophrenia and schizoaffective disorder.
Furthermore, the American Psychiatric Association (APA) recom-
mends (1B) that patients with TRS be treated with clozapine and
recommends (1B) patients with schizophrenia be treated with
clozapine if the risk for suicide attempts or suicide remains
substantial despite other treatments and suggests (2C) that
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patients with schizophrenia be treated with clozapine if the risk for
aggressive behavior remains substantial despite other treatments
[8]. Of note, clozapine is recommended in some clinical guidelines
for treatment-refractory bipolar disorder [9] with an uncertain
body of evidence suggesting beneficial effects on e.g. mania,
depression, rapid cycling and psychotic symptoms [10].
Even though clozapine is considered one of the most effective
medications and is listed in the WHO Model List of Essential
Medicines [11], there is frequently a delay in clozapine initiation,
leading to poorer mental health and functional outcomes [10, 12],
preceded by attempts of polypharmacy treatment without
evidence for effectiveness [13].
The scientific literature regarding clozapine is vastly increasing
and evidence-based psychiatry might help clinicians to judge the
best evidence and decision-makers and clinicians are overstrained
by the number of individual studies, reviews and meta-analyses [14].
Thus, with our quantitative meta-review of meta-analyses we
aimed at elucidating the state-of-the-art of efficacy, effectiveness,
tolerability and management of clozapine and clozapine-related
adverse-events in order to synthesize evidence, provide orienta-
tion for decision-makers and clinicians and identify treatment
gaps for future research.
METHODS
Information sources and search
This meta-review was pre-registered on PROSPERO
(CRD42020164135). Following the structure of the International
Statistical Classification of Diseases and Related Health Problems
10th Revision (ICD-10 WHO Version, 2015), we searched the
PubMed/MEDLINE database and the EMBASE databases using the
following search terms with limitation to systematic reviews
and/or meta-analyses: “clozapine” OR “leponex” OR “clozaril”.
The literature searches and selection were independently
performed by EW and PiyF and validated by AH. The titles and
the abstracts of each citation were screened manually, and the full
text of each potentially relevant citation was retrieved for detailed
review. Pharmacological or non-pharmacological clozapine aug-
mentation/combination strategies with the purpose of clinical
improvement were excluded a priori since evidence in this field
was already meta-reviewed by members of our group [15].
Furthermore, studies focusing on genetics and/or pharmacoge-
netics, brain-imaging studies, cost-effectiveness studies, and
animal studies were excluded. Three publications [16–18] were
added by hand since two were published after the search period
[16, 18] and one included sub-analyses for a new domain [17]
(see Fig. 1).
Eligibility criteria
The inclusion criteria were all meta-analyses published in English
between January 1, 1970, and December 19, 2019 (PubMed) and
1970–2019 (EMBASE) with quantitative data of people treated
with clozapine alone or clozapine vs any control (clozapine,
placebo, or non-clozapine antipsychotics). The major exclusion
criteria were the absence of clozapine-specific meta-analytic data.
We extracted clozapine-specific meta-analytic data on effective-
ness, efficacy, and tolerability of clozapine, management of
clozapine, and clozapine-related adverse events. The applied
search strategy according to The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19] is
shown in Fig. 1.
Data collection process
After full-text review, one researcher (EW) extracted quantitative
data from pairwise meta-analyses with validation by a second
researcher (PiyF). Network meta-analytic data was extracted if
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Fig. 1 Flowchart for literature search and study selection process [19]. Study selection flow diagram of meta-analyses providing
quantitative data. Three meta-analyses were manually identified.
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pairwise analyses were presented. If standardized mean difference
(SMD), mean difference (MD), risk difference (RD) > 0 demon-
strated a beneficial outcome for clozapine (e.g. more response or
less adverse events) then the direction ‘clozapine’, was extracted,
however, if <0 then the direction “control” was extracted. If RR,
odds ratio (OR), hazard ratio (HR) > 1 meant a beneficial outcome
for clozapine (e.g. more response or less adverse events/dropouts)
then the direction ‘clozapine’, otherwise ‘control’, was extracted.
Furthermore, we grouped outcomes into short-term (up to
12 weeks), medium-term (13–26 weeks), and long-term (over
26 weeks).
Fig. 2 Quantitative meta-review of clozapine-specific meta-analytic data: Efficacy. A Positive symptoms. FGA first-generation antipsychotic,
k number of studies, L long-term, M medium-term, n number of participants, RCT randomized controlled trial, S short-term, SGA second-
generation antipsychotic. Abbreviated study descriptions: Leucht et al., 2009a [76], Leucht et al., 2009b [76], Leucht et al., 2009c [79]. For
continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more response or less adverse events. B Negative symptoms.
FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants, RCT randomized controlled
trial, S short-term, SGA second-generation antipsychotic. Abbreviated study descriptions: Leucht et al., 2009a [76], Leucht et al., 2009b [76],
Leucht et al., 2009c [79]. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more response or less adverse
events. C Overall symptoms. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants,
RCT randomized controlled trial, S short-term, SGA second-generation antipsychotic. Abbreviated study descriptions: Leucht et al., 2009a [76],
Leucht et al., 2009b [76], Leucht et al., 2009c [79]. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more
response or less adverse events. D Global impression. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n
number of participants, RCT randomized controlled trial, S short-term, SGA second-generation antipsychotic. For continuous outcomes, SMD
> 0 means a beneficial outcome for clozapine (e.g. more response or less adverse events. E Quality of life and global functioning. CGAS
Children’s Global Assessment Scale, FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, MLDL Münchner
Lebensqualitäts–Dimensionen–Liste, n number of participants, RCT randomized controlled trial, S short-term, SGA second-generation
antipsychotic, SWN Subjective Wellbeing under Neuroleptics Scale, WHO-QOL: WHO-Quality of life. For continuous outcomes, SMD > 0 means
a beneficial outcome for clozapine (e.g. more response or less adverse events. F Other symptoms (cognition, hostility, depression) as a
continuous outcome. BPRS Brief Psychiatric Rating Scale, CGI clinical global impressions, FGA first-generation antipsychotic, k number of
studies, L long-term, M medium-term, n number of participants, PANSS Positive and Negative Syndrome Scale, RCT randomized controlled
trial, S short-term, SGA second-generation antipsychotic. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g.
more response or less adverse events. G Response to treatment. FGA first-generation antipsychotic, k number of studies, L long-term, M
medium-term, n number of participants, RCT randomized controlled trial, S short-term, SGA second-generation antipsychotic. For
dichotomous outcomes, RR > 1 means a beneficial outcome for clozapine (e.g. more response or less adverse events/dropouts). H Relapse.
FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants, RCT randomized controlled
trial, S short-term, SGA second-generation antipsychotic. abbreviated study descriptions: Leucht et al., 2009a [76], Leucht et al., 2009b [76],
Leucht et al., 2009c [79]. For dichotomous outcomes, RR > 1 means a beneficial outcome for clozapine (e.g. more response or less adverse
events/dropouts). I Dropouts. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants,
RCT randomized controlled trial, S short-term, SGA second-generation antipsychotic. For dichotomous outcomes, RR > 1 means a beneficial
outcome for clozapine (e.g. more response or less adverse events/dropouts).
E. Wagner et al.
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Data transformation
The data transformation process was conducted by two authors
(EW and SS) with validation by a third author (SL) using R statistical
software version 4.0.3 [20] and the package tidyverse version 1.1.3
[21] OR and RD were transformed to RR [22] while HR and
incidence rate ratio (IRR) was used as RR. MD was transformed into
SMD [23], and in case the total number of participants in the
control and experimental group were not given, equal groups
were assumed. A beneficial outcome for the experimental
intervention was represented with SMD > 0 or OR > 1, and minus
or inverse transformations were applied whenever the opposite
direction was reported. Due to limited data, adverse events of
clozapine add-on strategies were not able to be included in the
analyses.
Endpoints
Endpoints were defined as (1) efficacy of clozapine (SMD and RR),
(2) tolerability/adverse events of clozapine (SMD and RR), and (3)
efficacy of add-on strategies to improve clozapine-related adverse
events (SMD and RR).
Methodological quality assessment of included meta-analyses
The Assessing the Methodological Quality of Systematic Reviews 2
(AMSTAR-2) checklist [24] was used independently by two
reviewers (EW, PiyF). Disagreements were solved by consensus
with a third reviewer (AH). Then, meta-analyses were categorized
into different domains according to their objectives, taking into
consideration participant characteristics, comparisons, and out-
comes. In case of an overlap of two domains within one meta-
analysis, categorization was performed with a primary focus on
population characteristics (e.g. first-episode schizophrenia) before
outcomes (e.g. metabolic outcomes) (see Table 1).
RESULTS
1078 records were identified and the publications were added
manually [16–18]. After the removal of duplicates, 959 records
remained. A total of 767 records were excluded on the title/
abstract level. The remaining 192 publications were retrieved as
full texts and were further assessed for eligibility. From these, 112
records were included in this meta-review. 80 records were
excluded as they met at least one of the exclusion criteria on full
text-level (see Fig. 1). Since no evidence is considered an
important finding according to the Cochrane Handbook [25],
two clozapine-specific Cochrane Database reviews/meta-analyses
that yielded no quantitative data due to a lack of relevant studies
[26, 27], were included in our umbrella review.
Study characteristics/AMSTAR ratings
From the 112 included meta-analyses [10, 16–18, 26–131] a
majority reported data on clozapine as subgroup or sensitivity
analysis, whereas 34 exclusively targeted populations of clozapine
users (see Table 1). According to AMSTAR-2, 61 (54.5%) meta-
analyses were rated as high-quality. A description of the results of
each meta-analysis along with their overall quality is presented in
the Supplementary Tables (see Supplementary Tables S1 and S2,
https://github.com/sksiafis/clozapine_meta_review).
Endpoints
Efficacy of clozapine (SMD and RR)
Positive symptoms in schizophrenia: Clozapine appears to be
superior to FGAs in RCTs (short, medium, and long-term) with
small to medium effects sizes [48, 79, 125]. Clozapine appears to
be superior to risperidone in Japanese populations with a medium
effect size [29, 31]. For TRS, clozapine appears to be not
significantly superior to pooled SGAs in observational studies
[82], and not significantly superior to other single SGAs [100] in
RCTs. When FGAs/SGAs are pooled, clozapine appears to be
superior in improving positive symptoms in RCTs in TRS with a
small effect size [106] see Fig. 2A).
Negative symptoms in schizophrenia: Clozapine is not superior
to SGAs in observational studies [82], but to most FGAs in RCTs
with both small and large effect sizes [48, 79, 125]—except short-
term data vs chlorpromazine [100, 128]. There is conflicting
evidence regarding the superiority of clozapine vs. pooled SGAs in
TRS [100, 106] and clozapine appears inferior to quetiapine (short-
term, only 2 studies with n total= 142) with medium effect sizes
[29, 30, 76] and aripiprazole medium-term in RCTs with a small
effect size [61] (see Fig. 2B).
Overall symptoms in schizophrenia: Clozapine appears to be
superior to placebo in short-term RCTs with large effect sizes
[76, 78], superior to FGAs in RCTs with small to medium effect sizes
[44, 48, 79, 99, 125] and to SGAs in observational studies with a
small effect size [82] and quetiapine in long-term RCTs with a large
effect size [65]. For TRS, clozapine appears to be superior vs. CPZ
with a medium effect size [100], superior vs. mixed FGAs/SGAs in
RCTs with small effect sizes [85, 106], but the evidence is
suggestive that clozapine is not superior vs. other antipsychotics
in long-term RCTs [100, 106]. (see Fig. 2C).
Other efficacy measures in schizophrenia: Clozapine has a
favorable profile in terms of dropout due to inefficacy compared
to placebo with a large effect size [57] and to CPZ with a medium
effect size [99] and SGAs, namely risperidone with medium effect
sizes [29, 65, 67, 70, 76] and in terms of ACD rates compared to
FGAs with small effect sizes [48, 99, 125], grouped SGAs in
observational studies with a small effect size [82] and some single
SGAs (e.g. risperidone and quetiapine) with small effect sizes [65]
(see Fig. 2I).
With regard to relapse, clozapine appears to be superior to
FGAs long-term [79, 125], but evidence from meta-analyses
is inconsistent [64] (see Fig. 2H). With regard to response,
clozapine appears to be superior to placebo with large effect
sizes [57, 66], superior to FGAs short-term with small effect sizes
[48, 99, 106, 125], but not superior to single SGAs (e.g. quetiapine,
risperidone, olanzapine) [29, 30, 61, 67, 70, 122] (see Fig. 2G). As a
second-line agent, clozapine appears to be superior to risperidone
and other antipsychotics with small effect sizes (see Fig. 2D) [90].
Evidence does not support superiority of clozapine for hospitaliza-
tion rate vs. SGAs (see Supplementary Fig. 16) or reduction of
suicide/self-injurious behavior vs. SGAs in observational studies
[82] (see Supplementary Fig. 17), and does not support superiority
for anti-suicidal effects in long-term RCTs vs. olanzapine [29], but
meta-analytic evidence from one long-term trial (n= 980) showed
superior effects of clozapine vs. olanzapine [67] (see Supplemen-
tary Fig. 17). Meta-analytic evidence suggests superior effects of
clozapine on hostility compared to FGAs in RCTs in mixed short-,
medium-, and long-term RCTs with a medium effect size [50] (see
Fig. 2F) and on cognition vs. SGAs in TRS in observational studies
with a small effect size [82] (see Fig. 2F), whereas mostly
nonsignificant effects on cognition compared to FGAs and SGAs
[119] were observed in RCTs and even inferior effects vs. single
FGAs, e.g. sertindole [89] (see Fig. 2F). With regard to psychosocial
functioning, clozapine appears not to have significantly more
beneficial effects compared to SGAs [92] (see Fig. 2E). For quality
of life, available data is scarce (see Fig. 2E). A detailed report with
regard to different disease entities and levels is presented
in the Supplementary Results S1 (https://github.com/sksiafis/
clozapine_meta_review). For additional outcomes, please see
Supplementary Figs. S1–S19.
Other efficacy measures in BP and PDP: No superior efficacy of
clozapine vs. other antipsychotics could be shown for mania in
bipolar disorder short-term [45] (see Fig. 2F). For PDP, clozapine
E. Wagner et al.
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Fig. 3 Quantitative meta-review of clozapine-specific meta-analytic data: adverse-events. A Weight as continuous outcome. BMI body-
mass-index, k number of studies, kg kilogram, L long-term, M medium-term, n number of participants, RCT randomized-controlled trial, S
short-term, SGA second-generation antipsychotic. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more
response or less adverse events. B Lipid levels. k number of studies, L long-term, M medium-term, n number of participants, RCT randomized-
controlled trial, S short-term, SGA second-generation antipsychotic. C Glucose, insulin and inulin resistance levels. FGA first-generation
antipsychotic, k number of studies, L long-term, M medium-term, n number of participants, RCT randomized-controlled trial, S short-term, SGA
second-generation antipsychotic. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more response or less
adverse events. D Weight as dichotomous outcome. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n
number of participants, RCT randomized-controlled trial, S short-term, SGA second-generation antipsychotic. For dichotomous outcomes, RR
> 1 means a beneficial outcome for clozapine (e.g. more response or less adverse events/dropouts). E Extrapyramidal symptoms as measured
by scales. k number of studies, L long-term, M medium-term, n number of participants, RCT randomized-controlled trial, S short-term, SAS
Simpson–Angus Scale, SGA second-generation antipsychotic, TD tardive dyskinesia. For continuous outcomes, SMD > 0 means a beneficial
outcome for clozapine (e.g. more response or less adverse events. F Extrapyramidal symptoms as dichotomous outcome. EPS extrapyramidal
symptoms, FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants, RCT randomized-
controlled trial, S short-term, SGA second-generation antipsychotic. For dichotomous outcomes, RR > 1 means a beneficial outcome for
clozapine (e.g. more response or less adverse events/dropouts). G (Anti-)cholinergic symptoms. FGA first-generation antipsychotic, k number
of studies, L long-term, M medium-term, n number of participants, RCT randomized-controlled trial, S short-term, SGA second-generation
antipsychotic. For dichotomous outcomes, RR > 1 means a beneficial outcome for clozapine (e.g. more response or less adverse events/
dropouts). H Sedation and dizziness. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of
participants, RCT randomized-controlled trial, S short-term, SGA second-generation antipsychotic. For dichotomous outcomes, RR > 1 means a
beneficial outcome for clozapine (e.g. more response or less adverse events/dropouts). I Other CNS symptoms (insomnia, headache, seizures,
anxiety). FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of participants, RCT randomized-
controlled trial, S short-term, SGA second-generation antipsychotic. For dichotomous outcomes, RR > 1 means a beneficial outcome for
clozapine (e.g. more response or less adverse events/dropouts). J WBC abnormalities. FGA first-generation antipsychotic, k number of studies,
L long-term, M medium-term, n number of participants, RCT randomized-controlled trial, S short-term, WBC white blood count. For
dichotomous outcomes, RR > 1 means a beneficial outcome for clozapine (e.g. more response or less adverse events/dropouts). K Any adverse
event and dropouts due to adverse events. FGA first-generation antipsychotic, k number of studies, L long-term, M medium-term, n number of
participants, RCT randomized-controlled trial, S short-term. For dichotomous outcomes, RR > 1 means a beneficial outcome for clozapine (e.g.
more response or less adverse events/dropouts).
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seems to be superior vs. quetiapine short-term in terms of clinical
global impression with large effect sizes [51] (see Fig. 2D). A
detailed report with regard to different disease entities and levels
is presented in the Supplementary Results S1 (https://github.com/
sksiafis/clozapine_meta_review).
Tolerability of clozapine (SMD and RR)
Clozapine is equivocally associated with a significantly higher risk
for weight gain with small to medium effect sizes (see Fig. 3A) and
an increased risk to develop type 2 diabetes compared to most
other antipsychotics [93] and with significantly fewer EPS or use of
antiparkinson medication compared to FGAs with small effect
sizes [48, 81, 125], SGAs [121] with large effect size and especially
risperidone with a medium effect size [29, 96] (see Fig. 3E and F).
Despite an unfavorable profile regarding sedation/dizziness,
anticholinergic, hematological, and cardiac events, different
metabolic outcomes and dropouts due to adverse events
compared to both FGAs and SGAs with small to large effect sizes
(see Fig. 2B, C, G, H, J, K) clozapine is associated with a significantly
lower mortality [124]. A detailed report with regard to different
diseases entities and levels is presented in the Supplementary
Results S1 (https://github.com/sksiafis/clozapine_meta_review).
For additional outcomes, please see Supplementary Figs. S1–S19.
Efficacy of pharmacological add-on strategies to improve
clozapine-related adverse-events
Metformin and GLP1-RA as add-on strategies seem promising for
improving metabolic outcomes short-term with mostly small
effect sizes [108, 131], but also aripiprazole appears effective in
terms of short-term weight reduction and reduction of lipid levels
with small effect sizes [112]. Limited evidence is available for the
efficacy of topiramate for weight reduction [43]. Evidence is scarce
for clozapine-related hypersalivation and constipation treatment
[41, 49, 115] (see Fig. 4A, B). A detailed report with regard
to different disease entities and levels is presented in the
Supplementary Results S1 (https://github.com/sksiafis/clozapine_
meta_review) and in the Supplementary Figs. S18, 19.
DISCUSSION
In our meta-review, we aimed at synthesizing all available evidence
for clozapine’s efficacy and safety across all medical conditions
where clozapine is used. We were able to give a systematic
overview of all relevant clozapine indications and clozapine-
associated endpoints derived from a total of 112 meta-analyses.
Based on this overview and the methodological evaluation of all
included meta-analyses, guideline developers and clinicians are
now able to provide a strict risk-benefit evaluation taking into
consideration all dimensions of clozapine treatment.
Symptomatic endpoints
Clozapine is significantly superior to placebo and superior to FGAs
with regard to overall and positive symptoms according to high-
quality meta-analytic evidence from RCTs [48, 76]. Meta-analytic
evidence suggests significant superiority of clozapine in terms of
efficacy on overall and positive symptoms compared to most SGAs
[29, 85, 121, 122, 125] even though results are inconsistent [79].
With regard to evidence for clozapine’s effectiveness derived
from observational studies, clozapine is associated with signifi-
cantly lower hospitalization and ACD rate compared with other
SGAs [65, 82]. For multi-episode schizophrenia and TRS, the
superiority of clozapine compared to other SGAs is challenged
according to meta-analytic evidence derived from RCTs: specifi-
cally for multi-episode schizophrenia (excluding TRS), clozapine
appears to be not significantly different from e.g. amisulpride,
olanzapine, zotepine and risperidone in terms of overall symp-
toms [57]. For TRS, clozapine is presumed to be not more
efficacious than olanzapine, risperidone or ziprasidone in the
subanalyses including only TRS trials in overall symptoms in the
meta-analysis from Leucht et al. [79] being in line with the
evidence from the meta-analysis from Samara et al. [100], where
also only blinded RCTs were included and clozapine was not
significantly superior to most other APs with regard to overall
symptom reduction [100].
For treatment-resistant positive symptoms, clozapine seems to
have significantly superior beneficial effects compared to quetia-
pine and haloperidol on single-substance level, but not compared
to olanzapine [100]. When comparators are pooled as a group
(FGA+ SGA) clozapine was shown to have superior effects for
treatment-resistant overall and positive symptoms [85, 106].
Nevertheless, for overall and positive symptoms in TRS, incon-
sistent evidence is reported in meta-analyses due to differences in
study selections, study populations, in the handling of study
characteristics, and in methodological approaches [100, 106].
For treatment-resistant negative symptoms, clozapine was
shown to be slightly superior to FGAs [48] despite inconsistent
results [73], but—according to a large body of evidence—not
significantly superior in comparison to SGAs [29, 85, 121], and if,
then only on short-term [106]. Nevertheless, negative symptom
data did not include a separation of primary from secondary
negative symptoms, which hampers interpretability of the results.
For cognition and psychosocial functioning, clozapine is not
presumed to be significantly superior compared to other SGAs
[89, 92]. While evidence for the efficacy of clozapine for first-
episode psychosis is scarce [128], limited evidence suggests
superior effects for clozapine as a second-line agent compared to
other antipsychotics, such as, e.g. risperidone [90].
Clozapine shows beneficial effects on psychosocial function but
without superiority to other antipsychotics [92]. Inconclusive
results are available for pro-cognitive effects of clozapine vs. FGAs
and SGAs [89, 119, 126]. For children with schizophrenia and
childhood-onset schizophrenia, clozapine seems to have superior
efficacy compared with FGAs [60, 74]. Limited evidence is
available for schizophrenia and comorbid depression or comorbid
substance abuse, but when clozapine was compared with any
other antipsychotic drug plus an antidepressant or placebo,
patients treated with clozapine constantly scored better on
Hamilton scores [52], and clozapine was superior to other
antipsychotics in substance use [71] and to risperidone in
reducing craving for cannabis [118]. Furthermore, clozapine is
likely to have some beneficial effects on hostility [50], suicidal
behavior [56]—and maybe aggression versus others in schizo-
phrenia, at least when compared with FGAs [62]. Nevertheless,
negative evidence for suicidal behavior and self-injurious behavior
for clozapine vs. SGA in observational studies was also reported
[82]. Of note, meta-analytic evidence for the efficacy of clozapine
in suicidal symptoms is mainly from registry data and
non-randomized trials, whereas to our knowledge, only one high-
quality RCT [132] fosters the evidence and contributes to long-term
RCT data [29]. With regard to dosing, there is only little meta-
analytic evidence that in studies with mean clozapine dosages
above 400mg/day, clozapine was superior to risperidone, but not
olanzapine [79] and evidence of effects between clozapine
standard, low and very low dose regimes on overall outcome in
schizophrenia is sparse [114]. For bipolar disorder, the efficacy of
clozapine seems to be similar to other antipsychotics in manic
episodes [45]. For neurological disorders, the largest body of
evidence is available for PDP, where low-dose clozapine (range
from 12.5 to 50mg) showed beneficial effects on psychotic
symptoms) [51, 58] even though negative results are reported [127].
Non-symptomatic efficacy/effectiveness endpoints
Limited evidence hints at superior effects vs. SGAs in reducing
drug abuse in schizophrenia short and medium-term [71, 118].
With regard to relapse prevention, clozapine is superior to FGAs
[48, 77] and SGAs [125], even though results in the latter are
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inconsistent [64]. Mortality rate ratios seem to be lower in patients
continuously treated with clozapine compared to patients on non-
clozapine antipsychotics [82, 124]. Clozapine significantly reduces
hospitalization rates compared to non-clozapine SGAs [75, 82] and
all-cause discontinuation rates [65, 82].
Clozapine-related adverse-events and complications
There is a strong body of meta-analytic evidence for especially
unfavorable metabolic outcomes (e.g. weight gain) [78, 93], also
for first-episode schizophrenia patients [128]. In line with meta-
analytic evidence for weight gain and the increased risk for the
onset of metabolic syndrome, treatment guidelines for adult
patients with schizophrenia have previously suggested not to use
clozapine as a first-line agent [3]. The application among elderly
patients with schizophrenia remains to be further investigated
[17]. Meta-analytic evidence unequivocally suggests that clozapine
is associated with a lower risk for EPS and/or tardive dyskinesia
compared to other FGAs and SGAs [38, 81]. Of note, meta-analytic
evidence suggests clozapine as favorable therapeutic antipsycho-
tic agent for the event of TD [83]. Clozapine use significantly
increases the risk for gastrointestinal hypomotility/constipation
compared to other APs [104], but no meta-analytic data is
available for the prevalence of clozapine-related (sub-) ileus.
Clozapine appears to be the most unfavorable antipsychotic for
sedation compared to FGAs and other SGAs [29, 78]. With regard
to pneumonia, the only available meta-analytic evidence suggests
that clozapine significantly increases pneumonia risk compared to
no antipsychotic use [47], but in general, evidence suggests that
clozapine-related pneumonia [47, 133] might be overseen.
The incidence for clozapine-associated neutropenia is pre-
sumed to be 3.8% and severe neutropenia (agranulocytosis)
between 0.4% [18] and 0.9% [88], respectively according to two
meta-analyses of observational studies and—according to another
meta-analysis—the relative risk for neutropenia is not significantly
associated with any individual clozapine add-on antipsychotic
medication [87]. Death caused by clozapine-related agranulocy-
tosis appears to be at 0.05% [18]. Meta-analytic evidence suggests
a low event rate of both clozapine-related myocarditis (0.7%) and
cardiomyopathia (0.6%) [16]. Nevertheless, clozapine’s potential
effect to cause arrhythmia [28] might be overseen, as reflected in a
low amount of evidence. For PDP, low-dose clozapine appears to
be relatively safe compared to placebo with mixed results for the
effects on motor symptoms [51, 58].
Fig. 4 Add-on strategies for adverse-event management. A Treatment options for clozapine-associated metabolic dysfunctions. BMI body-
mass index, cm centimeter, GLP-1RA GLP-1 receptor agonist, HDL high-density lipoprotein, HOMA homeostatic model assessment for insulin
resistance, k number of studies, kg kilogram, L long-term, LDL low-density lipoprotein, M medium-term, n number of participants, RCT
randomized-controlled trial, S short-term. For continuous outcomes, SMD > 0 means a beneficial outcome for clozapine (e.g. more response or
less adverse events. B Treatment options for clozapine-associated hypersalivation. k number of studies, L long-term, M medium-term, n
number of participants, RCT randomized-controlled trial, S short-term. For dichotomous outcomes, RR > 1 means a beneficial outcome for
clozapine (e.g. more response or less adverse events/dropouts).
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Treatment of clozapine-related adverse events and
complications
Metformin [108], GLP-1RAs [105] and to a lesser extent
aripiprazole [112] seem to be beneficial add-on-agents for the
management of clozapine-related weight gain. Metformin was
superior to placebo in terms of weight loss and BMI [108]. GLP-
1RAs led to a significantly higher weight loss compared to control
(placebo or usual care) [105] and aripiprazole was superior with
regard to weight change and LDL-cholesterol compared to
placebo [112]. In all scenarios, a close risk-benefit evaluation has
to be performed, since e.g. the add-on use of aripiprazole was
significantly associated with agitation/akathisia and anxiety [112].
For the treatment of clozapine-related constipation, there is not
enough evidence from clinical trials to inform clinical practice [49],
as it is the case for clozapine-related sinustachycardia, where no
data for specific clinical interventions, e.g. the use of beta-blockers
is available from clinical trials [26].
The results of this meta-review should be interpreted with
caution due to the inherent limitations of the meta-analyses and
their included studies. The quality of meta-analyses was evaluated
using the AMSTAR-2 tool, which includes items for heterogeneity
and publication bias, yet further exploration of their impact on
meta-analytic estimates is out of the scope of this manuscript. In
addition, overlapping meta-analyses on the same topic may have
different results due to different eligibility criteria and statistical
methods [134], such as differences about the efficacy of clozapine
for treatment-resistance schizophrenia [100, 106]. Limitations of
the included studies could also impact meta-analytic estimates, i.e.
a meta-analysis of observational studies investigating mortality
during treatment with clozapine [135]. The potential impact of
study-level (e.g. rating scale used to measure symptom improve-
ment), and participant-level factors (such as race/ethnicity) or
other confounding factors specifically in observational studies
(such as concomitant medications) could not be easily addressed
at the level of an umbrella review. Our meta-review represents the
first comprehensive quantitative analysis of clozapine with regard
to its efficacy and safety in schizophrenia, schizoaffective and
bipolar disorder and PDP. Our meta-review outlines the superior
efficacy of clozapine compared to FGAs and most other SGAs in
schizophrenia and suggests beneficial outcomes in bipolar
disorder and PDP. Nevertheless, evidence to manage clozapine-
related adverse-events is sparse. In addition, more studies are
needed regarding the safety of clozapine beyond the scope of
schizophrenia-spectrum disorders. Our quantitative meta-review
suggests that if routine hematological monitoring and screening
for the early detection of myocarditis are performed, a close and
continuous risk-benefit evaluation with regard to cardiovascular
risk factors is key to improve clozapine-related outcomes.
REFERENCES
1. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during
treatment with chlozapine. Eur J Clin Pharmacol. 1977;11:193–198.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant
schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen
psychiatry. 1988;45:789–96.
3. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The
2009 schizophrenia PORT psychopharmacological treatment recommendations
and summary statements. Schizophrenia Bull. 2010;36:71–93.
4. Barnes TR. Evidence-based guidelines for the pharmacological treatment of
schizophrenia: recommendations from the British Association for Psycho-
pharmacology. J Psychopharmacol. 2011;25:567–620.
5. National Collaborating Centre for Mental H. National Institute for Health and
Clinical Excellence: Guidance. Psychosis and schizophrenia in adults: treatment
and management: updated edition 2014. London: National Institute for Health
and Care Excellence (UK) Copyright (c) National Collaborating Centre for Mental
Health; 2014.
6. Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. Worldwide
differences in regulations of clozapine use. CNS Drugs. 2016;30:149–61.
7. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum
ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resis-
tance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis
and terminology. Am J Psychiatry. 2017;174:216–29.
8. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases,
bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12:638–46.
9. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised
second edition–recommendations from the British Association for Psycho-
pharmacology. J Psychopharmacol. 2009;23:346–88.
10. Üçok A, Çikrikçili U, Karabulut S, Salaj A, Öztürk M, Tabak Ö, et al. Delayed
initiation of clozapine may be related to poor response in treatment-resistant
schizophrenia. Int Clin Psychopharmacol. 2015;30:290–295.
11. World Health Organisation. WHO Model list of Essential Medicines, 20th List.
2017.
12. Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of
delay in clozapine initiation on treatment outcomes in patients with treatment-
resistant schizophrenia: a systematic review. Psychiatry Res. 2018;268:114–22.
13. Thien K, O’Donoghue B. Delays and barriers to the commencement of clozapine
in eligible people with a psychotic disorder: a literature review. Early Interv
Psychiatry. 2019;13:18–23.
14. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic
reviews a day: how will we ever keep up? PLoS Med. 2010;7:e1000326.
15. Wagner E, Löhrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine aug-
mentation strategies—a systematic meta-review of available evidence. Treat-
ment options for clozapine resistance. J Psychopharmacol. 2019;33:423–35.
16. Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, et al. Systematic review
and meta-analysis of rates of clozapine-associated myocarditis and cardio-
myopathy. Aust NZ J Psychiatry. 2020;54:4867419898760–481.
17. Krause M, Huhn M, Schneider-Thoma J, Rothe P, Smith RC, Leucht S. Anti-
psychotic drugs for elderly patients with schizophrenia: a systematic review and
meta-analysis. Eur Neuropsychopharmacol. 2018;28:1360–70.
18. Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, et al. The prevalence of
agranulocytosis and related death in clozapine-treated patients: a compre-
hensive meta-analysis of observational studies. Psychol. Med. 2020;50:583–
94.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for sys-
tematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol.
2009;62:1006–12.
20. R Core Team. R :2019: A Language and Environment for Statistical Computing. R
Foundation for Statistical Computing, Vienna, Austria. Vol. 3. 2020. Available
online at https://www.R-project.org/.
21. Wickham et al. Welcome to the Tidyverse. J. Open Source Softw. 2019;4:1686.
22. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA
(editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd
Edition. Chichester (UK): John Wiley & Sons, 2019.
23. Borenstein MCH, Hedges L, Valentine J. Effect sizes for continuous data. In: The
handbook of research synthesis and meta-analysis. H. Cooper, L. V. Hedges, & J.
C. Valentine (Eds.). Russell Sage Foundation. 2009. p. 221–235.
24. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a
critical appraisal tool for systematic reviews that include randomised or non-
randomised studies of healthcare interventions, or both. BMJ (Clin Res ed).
2017;358:j4008.
25. Higgins. Cochrane handbook for systematic reviews of interventions version
5.1.0. 2011.
26. Lally J, Docherty MJ, MacCabe JH. Pharmacological interventions for clozapine-
induced sinus tachycardia. Cochrane Database Syst Rev. 2016;6:Cd011566.
27. Ayub M, Saeed K, Munshi TA, Naeem F. Clozapine for psychotic disorders in
adults with intellectual disabilities. Cochrane Database Syst Rev. 2015;9:
Cd010625.
28. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system
dysfunction in psychiatric disorders and the impact of psychotropic medica-
tions: a systematic review and meta-analysis. J Psychiatry Neurosci.
2016;41:89–104.
29. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S,
et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane
Database Syst Rev (Online). 2010;11:CD006633.
30. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine
versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst
Rev. 2013;11:Cd006625.
31. Bai Z, Wang G, Cai S, Ding X, Liu W, Huang D, et al. Efficacy, acceptability and
tolerability of 8 atypical antipsychotics in Chinese patients with acute schizo-
phrenia: a network meta-analysis. Schizophrenia Res. 2017;185:73–79.
32. Bak M, Fransen A, Janssen J, Van Os J, Drukker M. Almost all antipsychotics result
in weight gain: a meta-analysis. PLoS ONE. 2014;9:e94112 (no pagination).
E. Wagner et al.
15
Translational Psychiatry          (2021) 11:487 
33. Bartoli F, Crocamo C, Clerici M, Carra G. Second-generation antipsychotics and
adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neu-
ropsychopharmacol. 2015;25:1767–74.
34. Bartoli F, Lax A, Crocamo C, Clerici M, Carra G. Plasma adiponectin levels in
schizophrenia and role of second-generation antipsychotics: a meta-analysis.
Psychoneuroendocrinology. 2015;56:179–89.
35. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM, Jr.
All-cause treatment discontinuation in schizophrenia during treatment with
olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psy-
chopharmacol 2007;27:252–8.
36. Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction
and/or cessation and antipsychotics as specific treatments for tardive dyskine-
sia. Cochrane Database of Systematic Reviews 2018; 2018 (no pagination)
(CD000459).
37. Buhagiar K, Jabbar F. Association of first- vs. second-generation antipsychotics
with lipid abnormalities in individuals with severe mental illness: a systematic
review and meta-analysis. Clin Drug Investig. 2019;39:253–273.
38. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and
second-generation antipsychotics in comparative randomized controlled trials:
a meta-analysis. World Psychiatry. 2018;17:330–340.
39. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of
second-generation antipsychotics in patients with treatment-resistant schizo-
phrenia: a review and meta-analysis of randomized trials. Am J Psychiatry.
2001;158:518–526.
40. Cheine MV, Wahlbeck K, Rimon M. Pharmacological treatment of schizophrenia
resistant to first-line treatment: a critical systematic review and meta-analysis.
Int J Psychiatry Clin Pract. 1999;3:159–169.
41. Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for
clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs.
2019;33:225–238.
42. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-
generation antipsychotics in children and adolescents: a bayesian meta-analysis.
J Clin Psychopharmacol. 2012;32:309–316.
43. Correll CU, Maayan L, Kane J, De Hert M, Cohen D. Efficacy for psychopathology
and body weight and safety of topiramate-antipsychotic cotreatment in
patients with schizophrenia spectrum disorders: results from a meta-analysis of
randomized controlled trials. J Clin Psychiatry. 2016;77:e746–e756.
44. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation
antipsychotics. Arch Gen Psychiatry. 2003;60:553–564.
45. Delgado A, Velosa J, Zhang J, Dursun SM, Kapczinski F, de Azevedo Cardoso T.
Clozapine in bipolar disorder: a systematic review and meta-analysis. J Psychiatr
Res. 2020;125:21–27.
46. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanza-
pine for schizophrenia. Cochrane Database Syst Rev (Online). 2005;2:CD001359.
47. Dzahini O, Singh N, Taylor D, Haddad PM. Antipsychotic drug use and pneu-
monia: Systematic review and meta-analysis. J Psychopharmacol.
2018;32:1167–1181.
48. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic
medication for schizophrenia. Cochrane Database Syst Rev 2009; (no pagina-
tion)(CD000059).
49. Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for
antipsychotic-related constipation. Cochrane Database Syst Rev. 2017;1:
Cd011128.
50. Faay MDM, Czobor P, Sommer IEC. Efficacy of typical and atypical antipsychotic
medication on hostility in patients with psychosis-spectrum disorders: a review
and meta-analysis. Neuropsychopharmacology. 2018;43:2340–2349.
51. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating
dopamimetic psychosis in Parkinson’s disease: structured review and meta-
analysis. Eur Neuropsychopharmacol. 2007;17:165–171.
52. Furtado VA, Srihari V. Atypical antipsychotics for people with both schizophrenia
and depression. Cochrane Database Syst Rev. 2008;1:Cd005377.
53. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the
treatment of schizophrenia: systematic overview and meta-regression analysis.
Br Med J. 2000;321:1371–1376.
54. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, et al.
Mid-term and long-term efficacy and effectiveness of antipsychotic medications
for schizophrenia: a data-driven, personalized clinical approach. J Clin Psy-
chiatry. 2011;72:1616–1627.
55. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS.
Antipsychotics in adults with schizophrenia: comparative effectiveness of first-
generation versus second-generation medications: a systematic review and
meta-analysis. Ann Intern Med. 2012;157:498–511.
56. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-
analysis. Schizophr Res. 2005;73:139–145.
57. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N,
et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute
treatment of adults with multi-episode schizophrenia: a systematic review and
network meta-analysis. Lancet. 2019;394:939–951.
58. Iketani R, Kawasaki Y, Yamada H. Comparative utility of atypical antipsychotics
for the treatment of psychosis in Parkinson’s disease: a systematic review and
Bayesian network meta-analysis. Biol Pharm Bull. 2017;40:1976–1982.
59. Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in
Parkinson’s disease: systematic review and meta-analysis. BJPsych open.
2015;1:27–33.
60. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset
schizophrenia. Cochrane Database of Syst Rev 2007 (no pagination)(CD004027).
61. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. Aripi-
prazole versus other atypical antipsychotics for schizophrenia. Cochrane Data-
base Syst Rev. 2014;1:Cd006569.
62. Khushu A, Powney MJ. Haloperidol for long-term aggression in psychosis.
Cochrane Database Syst Rev. 2016;11:Cd009830.
63. Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N. Comparative efficacy
and safety of antipsychotics in the treatment of schizophrenia: a network meta-
analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017;13:1281–1302.
64. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse pre-
vention in schizophrenia: a systematic review and meta-analysis of second-
generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry.
2013;18:53–66.
65. Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of
oral second-generation antipsychotics in patients with schizophrenia and rela-
ted disorders: a systematic review and meta-analysis of direct head-to-head
comparisons. World Psychiatry. 2019;18:208–224.
66. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A review and
bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical
neuroleptic drugs compared with haloperidol and placebo. J Clin Psycho-
pharmacol. 2011;31:698–704.
67. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M,
et al. Quetiapine versus other atypical antipsychotics for schizophrenia.
Cochrane Database Syst Rev. 2010;1:Cd006625.
68. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, et al.
Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane
Database Syst Rev (Online). 2010;1:CD006628.
69. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W,
et al. Ziprasidone versus other atypical antipsychotics for schizophrenia.
Cochrane Database Syst Rev. 2009;4:Cd006627.
70. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al.
Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane
Database Syst Rev (Online). 2011;1:CD006626.
71. Krause M, Huhn M, Schneider-Thoma J, Bighelli I, Gutsmiedl K, Leucht S. Efficacy,
acceptability and tolerability of antipsychotics in patients with schizophrenia
and comorbid substance use. A systematic review and meta-analysis. Eur
Neuropsychopharmacol. 2019;29:32–45.
72. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al.
Efficacy, acceptability, and tolerability of antipsychotics in children and ado-
lescents with schizophrenia: a network meta-analysis. Eur Neuropsycho-
pharmacol. 2018;28:659–674.
73. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, et al.
Antipsychotic drugs for patients with schizophrenia and predominant or pro-
minent negative symptoms: a systematic review and meta-analysis. Eur Arch
Psychiatry Clin Neurosci. 2018;268:625–639.
74. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for
psychosis in adolescents. Cochrane Database Syst Rev. 2013;10:Cd009582.
75. Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA. The impact of
clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr
Scand. 2017;135:296–309.
76. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-
generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
Mol Psychiatry. 2009;14:429–447.
77. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention
in schizophrenia with new-generation antipsychotics: a systematic review and
exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry.
2003;160:1209–1222.
78. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative
efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-
treatments meta-analysis. Lancet. 2013;382:951–962.
79. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus
first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet.
2009;373:31–41.
E. Wagner et al.
16
Translational Psychiatry          (2021) 11:487 
80. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents
for second-generation antipsychotics: the minimum effective dose method.
Schizophr Bull. 2014;40:314–326.
81. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics
versus low-potency conventional antipsychotics: a systematic review and meta-
analysis. Lancet. 2003;361:1581–1589.
82. Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospita-
lization and all-cause discontinuation among patients with schizophrenia on
clozapine vs other oral second-generation antipsychotics: a systematic review
and meta-analysis of cohort studies. JAMA Psychiatry. 2019;76:1052–1062.
83. Mentzel TQ, et al. Clozapine monotherapy as a treatment for antipsychotic-
induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry 2018;79:17r11852.
84. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Pre-
valence of metabolic syndrome and metabolic abnormalities in schizophrenia
and related disorders—a systematic review and meta-analysis. Schizophr Bull.
2013;39:306–318.
85. Mizuno Y, McCutcheon RA, Brugger SP, Howes OD. Heterogeneity and efficacy
of antipsychotic treatment for schizophrenia with or without treatment resis-
tance: a meta-analysis. Neuropsychopharmacology 2020;45:622–631.
86. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-
resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161–166.
87. Myles N, Myles H, Xia S, Large M, Bird R, Galletly C, et al. A meta-analysis of
controlled studies comparing the association between clozapine and other
antipsychotic medications and the development of neutropenia. Aust NZ J
Psychiatry. 2019;53:403–412.
88. Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis
examining the epidemiology of clozapine-associated neutropenia. Acta Psy-
chiatr Scand. 2018;138:101–109.
89. Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen
T, Leucht S. Second-generation antipsychotic effect on cognition in patients
with schizophrenia–a meta-analysis of randomized clinical trials. Acta Psychiatr
Scand. 2015;131:185–196.
90. Okhuijsen-Pfeifer C, Huijsman E, Hasan A, Sommer I, Leucht S, Kahn RS, et al.
Clozapine as a first- or second-line treatment in schizophrenia: a systematic
review and meta-analysis. Acta Psychiatr Scand. 2018;138:281–288.
91. Okhuijsen-Pfeifer C, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ.
Demographic and clinical features as predictors of clozapine response in
patients with schizophrenia spectrum disorders: a systematic review and meta-
analysis. Neurosci Biobehav Rev. 2020;111:246–252.
92. Olagunju AT, Clark SR, Baune BT. Clozapine and psychosocial function
in schizophrenia: a systematic review and meta-analysis. CNS Drugs.
2018;32:1011–1023.
93. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al.
Comparative effects of 18 antipsychotics on metabolic function in patients with
schizophrenia, predictors of metabolic dysregulation, and association with
psychopathology: a systematic review and network meta-analysis. Lancet Psy-
chiatry. 2020;7:64–77.
94. Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of
leptin in schizophrenia: a meta-analysis. Can J Psychiatry 2015; Rev Canad
Psychiatr. 60:S26–S34.
95. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological
complications of second-generation antipsychotic use in children: a systematic
review and meta-analysis of randomized controlled trials. Drug Saf.
2011;34:651–668.
96. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al.
Second-generation antipsychotic drugs and extrapyramidal side effects: a sys-
tematic review and meta-analysis of head-to-head comparisons. Schizophr Bull.
2012;38:167–177.
97. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al.
Head-to-head comparisons of metabolic side effects of second generation
antipsychotics in the treatment of schizophrenia: a systematic review and meta-
analysis. Schizophr Res. 2010;123:225–233.
98. Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, et al. Sudden
cardiac and sudden unexpected death related to antipsychotics: a meta-analysis
of observational studies. Clin Pharmacol Ther. 2016;99:306–314.
99. Samara MT, Cao H, Helfer B, Davis JM, Leucht S. Chlorpromazine versus every
other antipsychotic for schizophrenia: a systematic review and meta-analysis
challenging the dogma of equal efficacy of antipsychotic drugs. Eur Neu-
ropsychopharmacol. 2014;24:1046–1055.
100. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al.
Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant
schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199–210.
101. Sarkar S, Grover S. Antipsychotics in children and adolescents with schizo-
phrenia: a systematic review and meta-analysis. Indian J Pharmacol.
2013;45:439–446.
102. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients
taking antipsychotics. Int Clin Psychopharmacol. 2011;26:130–140.
103. Sherwood M, Thornton AE, Honer WG. A quantitative review of the profile and
time course of symptom change in schizophrenia treated with clozapine. J
Psychopharmacol. 2012;26:1175–1184.
104. Shirazi A et al. Prevalence and predictors of Clozapine-associated constipation: a
systematic review and meta-analysis. Int J Mol Sci 2016; 17 (no pagination)(863).
105. Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, et al. Glucagon-
like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic
risk factors: a systematic review and individual participant data meta-analysis.
Diabetes Obes Metab. 2019;21:293–302.
106. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-
generation antipsychotics in treatment-refractory schizophrenia: systematic
review and meta-analysis. Br J Psychiatry. 2016;205:385–392.
107. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with
treatment-resistant schizophrenia: data from a systematic review and meta-
analysis. Can J Psychiatry. 2017;62:772–777.
108. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S. Metformin for clozapine
associated obesity: a systematic review and meta-analysis. PLoS ONE 2016; 11
(no pagination)(e0156208).
109. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-
generation antipsychotics and risk for diabetes in schizophrenia: systematic
review and meta-analysis. Br J Psychiatry. 2008;192:406–411.
110. Soares-Weiser K, Bechard-Evans L, Lawson AH, Davis J, Ascher-Svanum H. Time
to all-cause treatment discontinuation of olanzapine compared to other anti-
psychotics in the treatment of schizophrenia: a systematic review and meta-
analysis. Eur Neuropsychopharmacol. 2013;23:118–125.
111. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in com-
parison with clozapine for treatment-resistant schizophrenia: evidence from a
systematic review and meta-analyses. CNS Spectr. 2013;18:82–89.
112. Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of
aripiprazole augmentation of clozapine in schizophrenia: a systematic
review and meta-analysis of randomized-controlled trials. J Psychiatr Res.
2015;62:38–47.
113. Subramanian S, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W,
et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane
Database Syst Rev. 2010;10:CD006628.
114. Subramanian S, Vollm BA, Huband N. Clozapine dose for schizophrenia.
Cochrane Database Syst Rev. 2017;6:Cd009555.
115. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological inter-
ventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev.
2008;3:Cd005579.
116. Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta-
analyses of the efficacy of asenapine for acute schizophrenia: comparisons with
placebo and other antipsychotics. J Clin Psychiatry. 2012;73:1533–1540.
117. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A.
Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-
analysis of differential effects of antipsychotic medications. Early Interv Psy-
chiatry. 2016;10:193–202.
118. Temmingh HS, Williams T, Siegfried N, Stein DJ. Risperidone versus other anti-
psychotics for people with severe mental illness and co-occurring substance
misuse. Cochrane Database Syst Rev. 2018;1:Cd011057.
119. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer WG. The impact of atypical
antipsychotic medications on long-term memory dysfunction in schizophrenia
spectrum disorder: a quantitative review. J Psychopharmacol. 2006;20:335–346.
120. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: The effects of smoking on
the disposition of two commonly used antipsychotic agents, olanzapine and
clozapine. BMJ Open 2014;4 (no pagination)(e004216).
121. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in
comparison to clozapine: a systematic review of randomized trials. Schizophr
Res. 2002;56:1–10.
122. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication
versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000;2:
Cd000966.
123. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al.
Risk of metabolic syndrome and its components in people with schizophrenia
and related psychotic disorders, bipolar disorder and major depressive disorder:
a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
124. Vermeulen JM, van Rooijen G, van de Kerkhof M, Sutterland AL, Correll CU, de
Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a
systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr
Bull. 2019;45:315–329.
125. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness
in schizophrenia: A systematic review and meta-analysis of randomized trials.
Am J Psychiatry. 1999;156:990–999.
E. Wagner et al.
17
Translational Psychiatry          (2021) 11:487 
126. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neu-
ropsychological change to clozapine, olanzapine, quetiapine, and risperidone in
schizophrenia. Int J Neuropsychopharmacol. 2005;8:457–472.
127. Zhang H, Wang L, Fan Y, Yang L, Wen X, Liu Y, et al. Atypical antipsychotics for
Parkinson’s disease psychosis: a systematic review and meta-analysis. Neu-
ropsychiatr Dis Treat. 2019;15:2137–2149.
128. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy
and safety of individual second-generation vs. first-generation antipsychotics in
first-episode psychosis: a systematic review and meta-analysis. Int J Neu-
ropsychopharmacol. 2013;16:1205–1218.
129. Zhang Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the
treatment of schizophrenia on glucose: a network meta-analysis. BMC Psy-
chiatry 2017; 17 (no pagination)(373).
130. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, et al. Efficacy and
safety of adjunctive topiramate for schizophrenia: a meta-analysis of rando-
mized controlled trials. Acta Psychiatr Scand. 2016;134:385–398.
131. Zimbron J, Khandaker GM, Toschi C, Jones PB, Fernandez-Egea E. A systematic
review and meta-analysis of randomised controlled trials of treatments for
clozapine-induced obesity and metabolic syndrome. Eur Neuropsychopharma-
col. 2016;26:1353–1365.
132. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine
treatment for suicidality in schizophrenia: International Suicide Prevention Trial
(InterSePT). Arch Gen psychiatry. 2003;60:82–91.
133. de Leon J, Sanz EJ, Noren GN, De Las Cuevas C. Pneumonia may be more
frequent and have more fatal outcomes with clozapine than with other second-
generation antipsychotics. World Psychiatry. 2020;19:120–121.
134. Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis J, Naudet F. Vibration of
effects from diverse inclusion/exclusion criteria and analytical choices: 9216
different ways to perform an indirect comparison meta-analysis. BMC Med.
2019;17:174.
135. van der Zalm YC, Termorshuizen F, Selten JP. Concerns about bias in studies on
clozapine and mortality. Schizophr Res. 2019;204:425–426.
AUTHOR CONTRIBUTIONS
All authors contributed to drafting the work or revising it critically for important
intellectual content and gave final approval of the version to be published. All
authors contributed either substantially to the conception or design of the work or
the acquisition, analysis, or interpretation of data for the work. EW, SS, and AH are
accountable for all aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately investigated and
resolved.
FUNDING
Open Access funding enabled and organized by Projekt DEAL.
COMPETING INTERESTS
EW, SS, PF, DS, and AR reports no competing interests. WGH has received consulting
fees or sat on paid advisory boards for: AlphaSights, Guidepoint, In Silico,
Translational Life Sciences, Otsuka, AbbVie and Newron, and holds/held shares in
Translational Life Sciences, AbCellera and Eli Lilly. PF was honorary speaker for
Janssen-Cilag, Astra-Zeneca, Eli Lilly, Bristol Myers-Squibb, Lundbeck, Pfizer, Bayer
Vital, SmithKline Beecham, Wyeth, and Essex. During the last 5 years he was a
member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly, and Lundbeck.
Presently, he is a member of the advisory boards of Richter Pharma, Böhringer-
Ingelheim and Otsuka. SL has received honoraria as a consultant/advisor and/or for
lectures from Angelini, Böhringer Ingelheim, Geodon & Richter, Janssen, Johnson &
Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka, Recordati, SanofiAventis, Sandoz,
Sunovion, TEVA. AH has been invited to scientific meetings by Lundbeck, Janssen-
Cilag, and Pfizer, and he received paid speakerships from Desitin, Janssen-Cilag,
Otsuka and Lundbeck. He was member of Roche, Otsuka, Lundbeck and Janssen-
Cilag advisory boards.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41398-021-01613-2.
Correspondence and requests for materials should be addressed to Elias Wagner.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
E. Wagner et al.
18
Translational Psychiatry          (2021) 11:487 
